MIT: 95% of enterprise AI pilots fail to deliver measurable ROI

A new study from MIT’s NANDA initiative has found that 95% of generative AI pilots fail to deliver measurable ROI for companies – a failure rate rooted not in flawed models but in poor integration and misaligned priorities.

Dr. Tim O’Connell can unpack what this means for healthcare. He is CEO of emtelligent, which builds AI-powered natural language processing tools that extract structured insights from unstructured medical data to improve healthcare workflows, analytics and decision making.

Of the more than 40 pilot tests the company has run on its AI systems, O’Connell reports all have generated a successful outcome, with some projects – such as one processing 5.1 billion notes – delivering up to an 80% increase in structured biomarker data across six therapeutic areas.

As both a practicing physician and the man behind emtelligent, O’Connell has firsthand insights into building clinical AI that works for clinicians.

We spoke with him to get his expert views on the new study from MIT’s NANDA initiative, genAI ROI hurdles and ways to jump them, back-office ROI versus visibility spending, and working with vendors and distributed leadership.

Read the full article here.